NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive

Two Readouts Expected In 2022

 
• By Andrew McConaghie
  
NIH
The NIH's ACTIV-2 study is focused on accelerating development of antibody treatments and other therapies for non-hospitalized COVID-19 patients. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip